A major initiative in the UK will use miniature human organs, known as organoids, grown from patient cells to improve drug testing and reduce reliance on animal models. These tissue structures, smaller than a millimetre, can replicate key features of full-scale organs and demonstrate how they respond to disease and pharmaceutical treatments.
The research program, headquartered in Cambridge and supported by £20m in funding from the Medical Research Council, aims to establish a standardized library of organoids for use by both academic researchers and pharmaceutical companies. Scientists involved in the project emphasize that organoid testing offers advantages over traditional animal models, noting that most human diseases either do not occur in animals or manifest differently due to biological differences. Historical data shows that over 90% of drugs that successfully pass animal testing ultimately fail in human trials, prompting regulatory agencies in the US and Europe to encourage alternative testing methodologies.
The initiative represents part of a broader governmental strategy to accelerate the reduction of animal use in research through new approach methodologies, including organoid systems, organ-on-chip technology, and artificial intelligence applications. Initial research efforts will focus on organoids for inflammatory bowel diseases, cancer tumor models, and neurological conditions. An additional £2m from Innovate UK supports nine separate projects specifically targeting reductions in the use of higher-order animals such as dogs and monkeys in safety testing.
Recent statistics indicate that animal testing procedures in Britain declined 3.8% in the most recent reporting period, with mice, rats, fish and birds accounting for over 90% of procedures. Companies developing alternative testing platforms, such as those growing heart cells in gel spheres for cardiac safety evaluation, report potential to detect toxicity earlier in the drug development process, thereby preventing harmful candidates from reaching animal testing stages. Advocates for these new technologies highlight their potential to support truly personalized medicine approaches based on individual patient biology.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI